Latest News

Dow Jones Newswires: Celcuity stock soars after hours on breakthrough therapy designation for cancer drug

Shares of Celcuity Inc.
CELC,
-0.75%

were up 17% at $10.80 after hours as the U.S. Food and Drug Administration granted Breakthrough Therapy designation for a cancer drug.

The designation is for gedatolisib for certain patients with HR+/HER2- metastatic breast cancer.

Gedatolisib received Fast Track designation from the FDA in January.

Celcuity said its breakthrough application was supported by data from a Phase 1b study that assessed safety, tolerability and clinical activity in combination with palbociclib and fulvestrant.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

More in:Latest News

Leave a reply

Your email address will not be published. Required fields are marked *